Amplifying STING activation by biomimetic manganese mRNA nanovaccines for local and systemic cancer immunotherapy.

Clicks: 135
ID: 281586
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #30 of 35 articles by views in Journal of controlled release : official journal of the Controlled Release Society

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Messenger RNA (mRNA)-based vaccines have great potential in cancer treatment. However, poor lymphatic transport, insufficient targeted delivery, intracellular degradation and insufficient immune response without adjuvants limit the application of mRNA vaccines. Herein, a novel mRNA nanovaccine (HM@MnO-mRNA) was constructed by ovalbumin (OVA) mRNA-loaded MnO encapsulation with a hybrid membrane (HM) of dendritic cells (DCs) and bacterial membrane for enhancing cancer immunotherapy. In vitro results indicated that HM@MnO-mRNA nanovaccine could target DC2.4 cells, achieve lysosomal escape to enhance the expression of antigen, leading to the efficient antigen presentation and the activation of DC2.4 cells. In vivo results demonstrated that HM@MnO-mRNA nanovaccine could target and retain in lymph nodes (LNs), continuously stimulate antigen presentation, and thus trigger a strong T cell mediated immune response. The prepared nanovaccine could effectively prevent and control the occurrence and development of B16-OVA subcutaneous tumors. This study will provide a new mRNA cancer vaccine delivery platform for cancer immunotherapy.
Reference Key
he2025amplifying Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors He, Chunyan; Shi, Changzhou; Fang, Mingxi; Chang, Pengzhao; Hou, Pingfu; Zhang, Yingying; Li, Jingjing
Journal Journal of controlled release : official journal of the Controlled Release Society
Year 2025
DOI
10.1016/j.jconrel.2025.113788
URL
Keywords
cancer immunotherapy biomimetic nanoparticles lns targeting mrna nanovaccine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.